Regarding: Humar et al. The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk Kidney Transplant Recipients. Am J Transplant 2010;10:1228–1237
Maura Iversen
Part of the Endocrinology, Diabetes, and Metabolism Commons